Valuation: Labcorp Holdings Inc.

Capitalization 20.4B 17.5B 16.31B 15.17B 27.99B 1,757B 31.26B 197B 74.37B 824B 76.52B 74.93B 3,028B P/E ratio 2025 *
20.2x
P/E ratio 2026 * 17.7x
Enterprise value 24.93B 21.39B 19.93B 18.54B 34.21B 2,147B 38.2B 241B 90.88B 1,007B 93.5B 91.56B 3,700B EV / Sales 2025 *
1.79x
EV / Sales 2026 * 1.68x
Free-Float
99.96%
Yield 2025 *
1.19%
Yield 2026 * 1.21%
More valuation ratios * Estimated data
Dynamic Chart
1 day-1.42%
1 week-2.36%
Current month-7.16%
1 month-6.76%
3 months+12.25%
6 months+2.16%
Current year+6.28%
More quotes
1 week 242.8
Extreme 242.8
251.84
1 month 242.8
Extreme 242.8
265.72
Current year 209.38
Extreme 209.375
265.72
1 year 205.98
Extreme 205.98
265.72
3 years 191.97
Extreme 191.97
265.72
5 years 170.05
Extreme 170.05
317.17
10 years 97.79
Extreme 97.79
317.17
More quotes
Change 5d. change 1-year change 3-years change Capi.($)
-1.42%-2.36%+13.54%+1.18% 20.4B
-0.41%-3.98%+12.24%+110.33% 86.88B
-2.12%-4.35%+3.42%-34.29% 78.38B
-0.87%-2.50%+35.26%+50.39% 26.84B
-1.17%-4.30%-12.01%+29.52% 23.66B
-0.76%-0.70%+13.67%+24.89% 18.63B
-0.05%-0.39%+32.87%+216.79% 16.26B
-1.40%-0.69%+25.01%+2.07% 15.71B
-2.16%-0.26%+30.30%+233.45% 13.73B
-2.05%-1.23%+16.06%+26.50% 13.08B
Average -1.00%-2.08%+17.04%+66.08% 31.36B
Weighted average by Cap. -0.59%-3.04%+13.01%+52.76%
See all sector performances

Financials

2025 *2026 *
Net sales 13.9B 11.93B 11.11B 10.34B 19.08B 1,197B 21.3B 134B 50.69B 561B 52.15B 51.07B 2,064B 14.56B 12.49B 11.64B 10.83B 19.98B 1,254B 22.31B 141B 53.09B 588B 54.62B 53.49B 2,161B
Net income 917M 787M 733M 682M 1.26B 79B 1.41B 8.86B 3.34B 37.04B 3.44B 3.37B 136B 1.07B 915M 852M 793M 1.46B 91.8B 1.63B 10.29B 3.89B 43.04B 4B 3.92B 158B
Net Debt 4.53B 3.88B 3.62B 3.37B 6.21B 390B 6.94B 43.72B 16.51B 183B 16.98B 16.63B 672B 4.03B 3.46B 3.22B 3B 5.53B 347B 6.17B 38.89B 14.68B 163B 15.1B 14.79B 598B
More financial data * Estimated data
Logo Labcorp Holdings Inc.
Labcorp Holdings Inc. provides comprehensive laboratory services that help doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident decisions. The Company provides insights and advanced science to improve health and improve lives through its unparalleled diagnostics and drug development laboratory capabilities. The Company operates through two segments: Diagnostics Laboratories (Dx) and Biopharma Laboratory Services (BLS). The Diagnostics Laboratories segment includes routine testing and specialty/esoteric testing. Dx operates through a network of patient service centers, branches, rapid response laboratories, primary laboratories, and specialty laboratories. The Biopharma Laboratory Services segment consists of early development research laboratories and central laboratory services. The Company is also focused on clinical diagnostics and reproductive and women's health in the United States outside of New York and New Jersey.
Employees
65,450
More about the company
Date Price Change Volume
18/07/25 243.72 $ -1.42% 573,383
17/07/25 247.24 $ +0.51% 645,080
16/07/25 245.98 $ +0.13% 605,448
15/07/25 245.65 $ -1.66% 872,514
14/07/25 249.80 $ +0.07% 1,033,313

Delayed Quote Nyse, July 18, 2025 at 09:00 pm

More quotes
Trading Rating
Investor Rating
ESG MSCI
AA
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
20
Last Close Price
243.72USD
Average target price
278.95USD
Spread / Average Target
+14.46%
Consensus

Quarterly revenue - Rate of surprise